Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial

The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale—Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve, 2017.

Original languageEnglish (US)
JournalMuscle and Nerve
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Amyotrophic Lateral Sclerosis
Randomized Controlled Trials
Placebos
Biomarkers
Monoamine Oxidase Inhibitors
Monoamine Oxidase
Vital Capacity
Neuroprotective Agents
Disease Progression
rasagiline
Urine
Muscles
Survival
Pharmaceutical Preparations

Keywords

  • amyotrophic lateral sclerosis
  • biomarker
  • controlled clinical trial
  • MAO-B inhibitor
  • motor neuron disease
  • randomized
  • rasagiline

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium (Accepted/In press). Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve. https://doi.org/10.1002/mus.26335

Rasagiline for amyotrophic lateral sclerosis : A randomized, controlled trial. / The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium.

In: Muscle and Nerve, 01.01.2018.

Research output: Contribution to journalArticle

The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium 2018, 'Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial', Muscle and Nerve. https://doi.org/10.1002/mus.26335
The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle and Nerve. 2018 Jan 1. https://doi.org/10.1002/mus.26335
The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium. / Rasagiline for amyotrophic lateral sclerosis : A randomized, controlled trial. In: Muscle and Nerve. 2018.
@article{637ca4c8335d4732b038769eeb3cc8c3,
title = "Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial",
abstract = "Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale—Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve, 2017.",
keywords = "amyotrophic lateral sclerosis, biomarker, controlled clinical trial, MAO-B inhibitor, motor neuron disease, randomized, rasagiline",
author = "{The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium} and Statland, {Jeffrey M.} and Dan Moore and Yunxia Wang and Maureen Walsh and Tahseen Mozaffar and Lauren Elman and Nations, {Sharon P.} and Hiroshi Mitsumoto and Fernandes, {J. Americo} and David Saperstein and Ghazala Hayat and Laura Herbelin and Chafic Karam and Jonathan Katz and Wilkins, {Heather M.} and Abdulbaki Agbas and Swerdlow, {Russell H.} and Santella, {Regina M.} and Dimachkie, {Mazen M.} and Barohn, {Richard J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/mus.26335",
language = "English (US)",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Rasagiline for amyotrophic lateral sclerosis

T2 - A randomized, controlled trial

AU - The Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium

AU - Statland, Jeffrey M.

AU - Moore, Dan

AU - Wang, Yunxia

AU - Walsh, Maureen

AU - Mozaffar, Tahseen

AU - Elman, Lauren

AU - Nations, Sharon P.

AU - Mitsumoto, Hiroshi

AU - Fernandes, J. Americo

AU - Saperstein, David

AU - Hayat, Ghazala

AU - Herbelin, Laura

AU - Karam, Chafic

AU - Katz, Jonathan

AU - Wilkins, Heather M.

AU - Agbas, Abdulbaki

AU - Swerdlow, Russell H.

AU - Santella, Regina M.

AU - Dimachkie, Mazen M.

AU - Barohn, Richard J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale—Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve, 2017.

AB - Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale—Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve, 2017.

KW - amyotrophic lateral sclerosis

KW - biomarker

KW - controlled clinical trial

KW - MAO-B inhibitor

KW - motor neuron disease

KW - randomized

KW - rasagiline

UR - http://www.scopus.com/inward/record.url?scp=85057307266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057307266&partnerID=8YFLogxK

U2 - 10.1002/mus.26335

DO - 10.1002/mus.26335

M3 - Article

C2 - 30192007

AN - SCOPUS:85057307266

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

ER -